- Recordati’s first-quarter (1Q) Ebitda surpassed estimates, recording EU244.0 million instead of the estimated EU238 million.
- The company’s operating income was slightly lower than expected, achieving EU186.9 million against the estimated EU190.8 million.
- Investor sentiments for Recordati are varied, with 5 buys, 6 holds, and 1 sell rating.
- Outdoor conference call is expected at 4 p.m., local Milan time.
A look at Recordati SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Recordati SpA, a pharmaceutical company known for its global reach and diverse product portfolio, has been assessed using Smartkarma Smart Scores across various key factors. This evaluation paints a picture of a company with a promising long-term outlook. While the Value score indicates room for improvement, Recordati SpA scores moderately in Dividend, Growth, Resilience, and notably high in Momentum. These scores collectively suggest a company that is well-positioned for sustained growth and market performance in the pharmaceutical industry.
The analysis of Recordati SpA‘s Smartkarma Smart Scores highlights a positive trajectory for the company’s future prospects. With a strong emphasis on Momentum and supported by solid scores in Dividend, Growth, and Resilience, Recordati SpA appears to be on a path towards continued success. As a manufacturer of prescription and non-prescription pharmaceuticals, as well as rare disease treatments, the company’s strategic position in the market coupled with favorable scores across key factors bodes well for its outlook in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
